Bret M. Benton
About
Bret M. Benton is a scholar working on Infectious Diseases, Molecular Biology and Clinical Biochemistry.
According to data from OpenAlex, Bret M. Benton has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 13 papers in Molecular Biology and 7 papers in Clinical Biochemistry. Recurrent topics in Bret M. Benton's work include Antimicrobial Resistance in Staphylococcus (14 papers), Bacterial Identification and Susceptibility Testing (7 papers) and Antibiotic Resistance in Bacteria (6 papers). Bret M. Benton is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (14 papers), Bacterial Identification and Susceptibility Testing (7 papers) and Antibiotic Resistance in Bacteria (6 papers). Bret M. Benton collaborates with scholars based in United States, France and Switzerland. Bret M. Benton's co-authors include Kevin M. Krause, P.P.A. Humphrey, Christopher S. Lunde, Dmitri Debabov, Jeremy Thorner, James W. Janc, Mathai Mammen, Dane E. Karr, Koné Kaniga and Ray Chang and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Molecular and Cellular Biology.
In The Last Decade
Bret M. Benton
25 papers receiving 1.3k citations
Peers
Bret M. Benton
Dmitri Debabov United States
Jeffrey B. Locke United States
John Pace United States
Klaudia Kosowska-Shick United States
Paul Majcherczyk Switzerland
Céline Vidaillac United States
Steve N. Leonard United States
S M Seo United States
M Konno Japan
Adam Belley United States
Citations per year, relative to Bret M. Benton Bret M. Benton (= 1×)
peers
Dmitri Debabov
Countries citing papers authored by Bret M. Benton
Since
Specialization
Citations
This map shows the geographic impact of Bret M. Benton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bret M. Benton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bret M. Benton more than expected).
Fields of papers citing papers by Bret M. Benton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bret M. Benton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bret M. Benton. The network helps show where Bret M. Benton may publish in the future.
Co-authorship network of co-authors of Bret M. Benton
This figure shows the co-authorship network connecting the top 25 collaborators of Bret M. Benton. A scholar is included among the top collaborators of Bret M. Benton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bret M. Benton. Bret M. Benton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rath, Christopher M., Bret M. Benton, Javier de Vicente, et al.. (2017). Optimization of CoaD Inhibitors against Gram-Negative Organisms through Targeted Metabolomics. ACS Infectious Diseases. 4(3). 391–402.
2.
Ross, Audrey G., Bret M. Benton, Donovan N. Chin, et al.. (2015). Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space. Bioorganic & Medicinal Chemistry Letters. 25(17). 3468–3475.
3.
Song, Yang, Christopher S. Lunde, Bret M. Benton, & Brian J. Wilkinson. (2013). Studies on the Mechanism of Telavancin Decreased Susceptibility in a Laboratory-Derived Mutant. Microbial Drug Resistance. 19(4). 247–255.
4.
Krause, Kevin M., Johanne Blais, Christopher S. Lunde, et al.. (2012). In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 74(4). 429–431.
5.
Song, Yang, Christopher S. Lunde, Bret M. Benton, & Brian J. Wilkinson. (2012). Further Insights into the Mode of Action of the Lipoglycopeptide Telavancin through Global Gene Expression Studies. Antimicrobial Agents and Chemotherapy. 56(6). 3157–3164.
6.
Farrell, David J., Kevin M. Krause, & Bret M. Benton. (2011). In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagnostic Microbiology and Infectious Disease. 69(3). 275–279.
7.
Hegde, Sharath S., et al.. (2010). Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. Journal of Antimicrobial Chemotherapy. 65(4). 725–728.
8.
Lunde, Christopher S., et al.. (2010). Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum ofStaphylococcus aureus. Antimicrobial Agents and Chemotherapy. 54(5). 2198–2200.
9.
Krause, Kevin M., Steven L. Barriere, Michael M. Kitt, & Bret M. Benton. (2010). In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagnostic Microbiology and Infectious Disease. 68(2). 181–185.
10.
Lunde, Christopher S., et al.. (2009). Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II. Antimicrobial Agents and Chemotherapy. 53(8). 3375–3383.
11.
Draghi, Deborah C., Bret M. Benton, Kevin M. Krause, et al.. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. Journal of Antimicrobial Chemotherapy. 62(1). 116–121.
12.
Krause, Kevin M., et al.. (2008). In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy. 52(7). 2647–2652.
13.
Gotfried, Mark H., Jeng‐Pyng Shaw, Bret M. Benton, et al.. (2007). Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics. Antimicrobial Agents and Chemotherapy. 52(1). 92–97.
14.
Benton, Bret M., Eefjan Breukink, Dmitri Debabov, et al.. (2007). O258 Telavancin inhibits peptidoglycan biosynthesis through preferential targeting of transglycosylation: evidence for a multivalent interaction between telavancin and lipid II. International Journal of Antimicrobial Agents. 29. S51–S52.
15.
Higgins, Deborah L., Ray Chang, Dmitri Debabov, et al.. (2005). Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 49(3). 1127–1134.
16.
Benton, Bret M., et al.. (2004). Large-Scale Identification of Genes Required for Full Virulence ofStaphylococcus aureus. Journal of Bacteriology. 186(24). 8478–8489.
17.
Wilson, Linda K., Bret M. Benton, Sharleen Zhou, Jeremy Thorner, & Greg S. Martin. (1995). The Yeast Immunophilin Fpr3 Is a Physiological Substrate of the Tyrosine-specific Phosphoprotein Phosphatase Ptp1. Journal of Biological Chemistry. 270(42). 25185–25193.
18.
Benton, Bret M., et al.. (1994). A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus.. The Journal of Cell Biology. 127(3). 623–639.
19.
Benton, Bret M., Wai-Kwong Eng, John J. Dunn, et al.. (1990). Signal-Mediated Import of Bacteriophage T7 RNA Polymerase into the Saccharomyces cerevisiae Nucleus and Specific Transcription of Target Genes. Molecular and Cellular Biology. 10(1). 353–360.
20.
Benton, Bret M., Wai-Kwong Eng, J J Dunn, et al.. (1990). Signal-mediated import of bacteriophage T7 RNA polymerase into the Saccharomyces cerevisiae nucleus and specific transcription of target genes.. Molecular and Cellular Biology. 10(1). 353–360.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dmitri Debabov Breakdown of academic impact, for papers by Jeffrey B. Locke Breakdown of academic impact, for papers by John Pace Breakdown of academic impact, for papers by Klaudia Kosowska-Shick Breakdown of academic impact, for papers by Paul Majcherczyk Breakdown of academic impact, for papers by Céline Vidaillac Breakdown of academic impact, for papers by Steve N. Leonard Breakdown of academic impact, for papers by S M Seo Breakdown of academic impact, for papers by M Konno Breakdown of academic impact, for papers by Adam Belley